Skip to content

Safety evaluation of excessive intake of food, Watanabe Oyster DHMBA Jelly, in healthy adult men and women

Safety evaluation of excessive intake of food, Watanabe Oyster DHMBA Jelly, in healthy adult men and women - Safety evaluation of excessive intake of food, Watanabe Oyster DHMBA Jelly, in healthy adult men and women

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000027093
Enrollment
11
Registered
2017-04-21
Start date
2017-04-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult

Interventions

Sponsors

TTC Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Healthy adult males and females from 20 to 64 years of age

Exclusion criteria

Exclusion criteria: (1) Subjects who routinely use health food richly containing DHMBA or oyster meat extract (2) Subjects judged as unsuitable for this study based on the results of clinical examination or cardiopulmonary abnormality (3) Subjects having possibilities for emerging allergy related to the study (4) Subjects having a disease requiring regular medication or a history of serious diseases for which medication was required (5) Subjects who are judged as unsuitable for the study based on the results of clinical and physical examination on preliminary examination (6) Subjects who have participated in other clinical studies (7) Subjects who intend to become pregnant or lactating (8) Subjects who are judged as unsuitable for the study based on the results of lifestyle questionnaire (9) Subjects judged as unsuitable for the study by the investigator for other reasons

Design outcomes

Primary

MeasureTime frame
Hematologic test Blood biochemistry test Urine analysis Blood pressure/pulsation Weight/ body mass index Doctor's questions Adverse event Evaluate at points of 2-week and 4-week of consumption and 2 weeks after the end of consumption period.

Countries

Japan

Contacts

Public ContactHiroyasu Shimada

TTC Co., Ltd. Clinical Research Planning Department

h.shimada@ttc-tokyo.co.jp03-5459-5329

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026